Son Espases invests nearly €1 million in three new clean rooms for therapies and medicines

Oct 3, 2026 | Actualidad, Current affairs, Featured, Interview, Portada, Post, Revista Lloseta, Thursday Daily Bulletin, Tradition

Son Espases University Hospital will invest nearly €1 million over the next three months to create three new clean rooms, which are due to be completed by the end of the year. The facilities will provide a total of 60 square metres for processing cell therapies and preparing medicines under sterile conditions.

Clean rooms are controlled spaces designed to maintain extremely low levels of airborne particles, dust and microorganisms, conditions required for the processing of certain cell therapies.

The new infrastructure will allow the hospital to expand the range of services available to residents of the Balearic Islands and is expected to generate annual savings of approximately half a million euros on these types of medicines.

One of the facilities will be a pharmacy clean room for cytostatic medicines, which are used in therapies to treat cancer and autoimmune diseases.

The facility will cover 40 square metres and represents an investment of €382,230. Preparing cytostatic medicines directly at Son Espases is expected to save approximately €230,000 per year.

TDB keeps you informed. Follow us on: Facebook, Twitter and Instagram

Son Espases invests nearly €1 million in three new clean rooms for therapies and medicines

The hospital has also invested €417,128 in another clean room for cell therapy, a cryopreservation room and a quality control laboratory for the Haematology Service.

This second area will occupy 20 square metres and will be used to prepare haematological treatments. The facilities will also enable Son Espases to continue increasing the number of CAR-T cell therapies.

CAR-T therapy is an advanced form of immunotherapy in which a patient’s own T cells, or lymphocytes, are genetically modified so that they can recognise and attack cancer cells.

The therapy benefits patients receiving oncohaematological treatments and is particularly relevant for people over the age of 65 who experience a relapse and are not candidates for a transplant, as their own cells can be used to begin the healing process.